European Patent Office Backs AstraZeneca's Symbicort Patent

Law360, New York (March 9, 2005, 12:00 AM EST) -- The European Patent Office has upheld the validity of the European combination patent for Swedish-U.K. drug maker AstraZeneca’s asthma treatment Symbicort, which had faced a challenge by several generic manufacturers.

As a result, no generic manufacturer can launch an equivalent product until AstraZeneca’s data exclusivity has expired or the generic company has submitted its own regulatory package, utilizing its own clinical data.

Astrazeneca has data protection for the drug in most major European until 2010. The European combination patent expires in 2012 with extension by supplementary...
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.